Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 244 clinical trials
  • 0 views
  • 13 May, 2022
  • 45 locations
Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC

ceritinib as the first ALK tyrosine kinase inhibitor (TKI)therapy.

cancer
lorlatinib
anaplastic lymphoma
cancer treatment
kinase inhibitor
  • 4 views
  • 01 May, 2022
  • 20 locations
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib is a more potent and more specific

consolidation therapy
blast cells
flt3 internal tandem duplication
serum bilirubin level
myelodysplastic syndromes
  • 11 views
  • 24 Feb, 2022
  • 1 location
KRT-232 and TKI Study in Chronic Myeloid Leukemia

intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and

leukemia
chronic phase chronic myeloid leukemia
tyrosine
nilotinib
dasatinib
  • 12 views
  • 05 Apr, 2022
  • 24 locations
Study of Infigratinib in Children With Achondroplasia

) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The

tyrosine kinase inhibitor
  • 45 views
  • 21 Apr, 2022
  • 18 locations
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

This study is about an anticancer drug called ponatinib which is a tyrasine kinase inhibitor given with chemotherapy to children, teenagers, and young adults up to 21 years of age with

  • 2 views
  • 10 May, 2022
  • 50 locations
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib.

EGFR
osimertinib
egfr t790m
  • 0 views
  • 19 Apr, 2022
  • 16 locations
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

chronic lymphocytic leukemia
lymphoid leukemia
leukemia
gilbert's syndrome
platelet count
  • 22 views
  • 26 Mar, 2022
  • 14 locations
Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)

The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study.

  • 16 views
  • 13 May, 2022
  • 38 locations
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations …

measurable disease
ROS1
cancer
tyrosine
lymphoma
  • 0 views
  • 26 Mar, 2022
  • 26 locations